The present invention provides formulations comprising polymers and therapeutics and methods for their manufacture. The present invention also provides medical devices coated with such formulations and methods for their manufacture. The drug-loaded polymer formulations, solutions, and films tailor the drug release characteristics for medical devices.

The disclosure relates to a central venous catheter, preparation method thereof and a medical device having the same. The central venous catheter comprises a tube body and a coating formed on the surface of tube body, coating being formed of a coating composition comprising at least one photosensitive functional compound and at least one photocurable polymer. The central venous catheter of the disclosure can prevent thrombosis, dissolve primary thrombus, and possess super-lubricated surface and firm coating bonding.

The invention relates to a coating for an implant component, a method for producing an implant component having said coating, and a use of said coating on an implant component. The coating is intended for an implant component, in particular a spinal implant component, and is a TiNb coating which has, in addition to an atom % proportion of Ti and an atom % proportion of Nb, an atom % proportion of 5-30 atom % of Ag.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrin variant is applied as a coating on an implantable device, such as a stent or a catheter.

Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.

The present disclosure provides for a medical device or a substrate coated with polydopamine which is further linked to ligands such as antibodies and/or antibody fragments. The polydopamine coating and the ligands may be linked through a linker such as an organic polymer.

A coating for a medical device or appliance may include a fluoropolymer and a polyimide. Such coatings may provide a lubricious exterior surface that facilitates insertion or displacement of a medical device in a body lumen. Some coatings that include a fluoropolymer and a polyimide may, among other functions and characteristics, provide increased strength and/or durability relative to some other coatings.

The present invention relates to improved clot retrieval devices, wherein at least the part of the device intended to be in contact with a clot is coated with at least one chromatin binding agent selected from the group consisting of digoxigenin, a digoxigenin derivative, distamycin and a distamycin derivative. The present invention also relates to a method of producing said improved clot retrieval device. The present invention also relates to a method of prevention and/or treatment of stroke in a subject, comprising removing at least one clot using the clot retrieval device coated with said least one chromatin binding agent.

A balloon catheter that includes an elongated main body extending in an axial direction and a balloon connected to the distal portion of the elongated main body. The balloon includes an interior and is inflatable and deflatable. The balloon catheter also includes a plurality of elongate bodies extending radially away from the outer surface of the balloon. The elongate bodies are crystals of a water-insoluble drug. The elongate bodies each possess an independent longitudinal axis. Each of the elongate bodies includes a base portion at the proximal end of the elongate body. A plurality of elongate body proximal portions extend radially inwardly from the base portion of each of the elongate bodies toward the interior of the balloon. The elongate body proximal portions are continuous extensions of the crystal of the water-insoluble drug.